No Data
No Data
Tradepulse Power Inflow Alert: Eli Lilly & Company Moves Up Over 13 Points After Signal
Amgen Analyst Ratings
J&J Sues HHS Over 340B Hospital Drug-discount Program
Amgen Slips as Cantor Cites Safety Concerns Linked to Obesity Candidate
Cantor Fitzgerald Maintains Overweight Rating On Amgen With $405 Price Target, Projecting $33.2B Revenue In 2024; Highlights Pipeline Risks And -4% BMD Loss In AMG-133 Phase 1 Trial
AbbVie's Schizophrenia Failure Disappoints But Analysts Show Confidence In Immunology Portfolio